Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03394053 · ClinicalTrials.gov registry record
The Mechanistic Biology of Primary Immunodeficiency Disorders
A clinical trial of Primary Immunodeficiency Disorders, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 2,500
- Enrollment target
- 2
- Study locations
NCT03394053: Recruiting study of Primary Immunodeficiency Disorders, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT03394053 is a study of Primary Immunodeficiency Disorders that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,500 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03394053, a study of Primary Immunodeficiency Disorders, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: Primary immunodeficiency disorders, or PIDs, are diseases that weaken the immune system. This makes it easier for a person to get sick. Some PIDs are mild and may not be diagnosed until later in life. Other kinds are severe and can be identified shortly after birth. Researchers want to learn more about PIDs by comparing data from relatives and healthy volunteers to people with a PID. Objective: To learn more about PIDs, including their genetic causes. Eligibility: People ages 0-90 with a PID or their healthy biological relatives the same ages Healthy volunteers ages 18-75 Design: Participants will be screened with a medical history, physical exam, and HIV blood test. They may have a pregnancy test. Participants may repeat the screening tests. Blood taken at screening will be used for genetic tests and research tests. Participants will be told test results that affect their health. Some blood will be stored for future research. Adult participants with a PID may have a small piece of skin removed. The area will be numbed. A small tool will take a piece of skin about the size of a pencil eraser. Researchers may collect fluid or tissue samples from PID participants regular medical care. They will use them for research tests. Participants with a PID will have 3 follow-up visits over 10 years (for infants, 2 years). Visits will include a physical exam, medical history, and blood draw. Participants with a PID and their relatives will be called once a year for 10 years. They will talk about how they are feeling and if they have developed any new symptoms or illnesses. ...
Primary Outcome
comparing these subjects to the large cohort of data in the Exome Aggregation Consortium (ExAC) Browser (Beta), which is available through http://exact.broadinstitute.org.
Conditions Studied
Study Locations (2)
District of Columbia
- Children's National Health System (CNHS) - Washington D.C.
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2040-12-31 |
What NCT03394053 shows while recruiting
NCT03394053 is an observational study that tracks outcomes without assigning an intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Primary Immunodeficiency Disorders appearing as the primary indexed condition, and to 0 interventions.
NCT03394053 reports a single indexed study location in District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT03394053 about?
NCT03394053 is a clinical study titled "The Mechanistic Biology of Primary Immunodeficiency Disorders". Background: Primary immunodeficiency disorders, or PIDs, are diseases that weaken the immune system. This makes it easier for a person to get sick. Some PIDs are mild and may not be diagnosed until later in life. Other kinds are severe and can be identified shortly after birth. Researchers want to ...
What is the current status of trial NCT03394053?
This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2018-05-30. Estimated completion is 2040-12-31.
What conditions does trial NCT03394053 study?
This clinical trial studies the following conditions: Primary Immunodeficiency Disorders.
Who is sponsoring clinical trial NCT03394053?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03394053 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI